Acceleron Pharma Reports Third Quarter 2016 Financial and Operational Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- FedEx pilots ratify new collective bargaining agreement
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
Acceleron Pharma (XLRN) Misses Q3 EPS by 2c
November 3, 2016 5:01 PM EDTAcceleron Pharma (NASDAQ: XLRN) reported Q3 EPS of ($0.55), $0.02 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $3 million versus the consensus estimate of $4.08 million.
For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.
... More